Atrial Fibrillation Ablation in Octogenarians: Where Do We Stand?

被引:0
作者
Gevorg Stepanyan
Edward P. Gerstenfeld
机构
[1] University of California,
[2] San Francisco,undefined
来源
Current Cardiology Reports | 2013年 / 15卷
关键词
Atrial fibrillation; Ablation; Elderly; Octogenarians; Stroke; Anticoagulation;
D O I
暂无
中图分类号
学科分类号
摘要
The prevalence of atrial fibrillation increases significantly with age, affecting nearly 10 % of adults greater than 80 years of age. Complications from atrial fibrillation, including stroke, also increase with age. Medical therapy includes anticoagulation, ventricular rate control, and if symptoms persist, maintenance of sinus rhythm with antiarrhythmic drugs. However, anticoagulation and antiarrhythmic therapy is often challenging in the elderly due to side effects, comorbidities, and heightened sensitivity to medications. Catheter based ablation of atrial fibrillation is an effective treatment for paroxysmal atrial fibrillation. However, the major randomized controlled trials, such as Thermocool AF and STOP-AF studies, have excluded the elderly patients. Current guidelines suggest caution when considering ablation for elderly patients due to a lack of available data. We will review recent studies that have observed the outcomes of atrial fibrillation ablation in the elderly, specifically those studies that included octogenarians.
引用
收藏
相关论文
共 88 条
[1]  
Williams E(2011)Catheter ablation of atrial fibrillation in elderly Curr Opin Cardiol 26 25-9
[2]  
Hall B(2013)Comparison of atrial fibrillation in the young vs that in elderly: a review Cardiol Res Pract 2012 1-16
[3]  
Traub D(2010)Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis J Am Coll Cardiol 56 827-37
[4]  
Bahnson T(2012)Catheter ablation of atrial fibrillation in octogenarians: safety and outcomes J Cardiovasc Electrophysiol 23 687-93
[5]  
Hranitzky P(2013)The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy Eur Heart J 34 170-6
[6]  
Zareba W(2009)Catheter ablation of atrial fibrillation in the elderly: where do we stand? Cardiol J 16 113-20
[7]  
Sankaranarayanan R(1988)The cardiac arrhythmia suppression trial (CAST) N Engl J Med 321 386-8
[8]  
Kirkwood G(2007)Amiodarone for atrial fibrillation N Engl J Med 356 935-41
[9]  
Dibb K(2012)HRS/EHRA/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research Hear Rhythm 2012 632-96
[10]  
Clifford G(2008)Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians J Cardiovasc Electrophysiol 19 807-11